SummaryThis is a non-randomised trial with two experimental arms. Participants with new diagnosed diffuse anaplastic Wilm's Tumour (DAWT) will receive a regimen of UH-3, consisting of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with favourable histology Wilm's Tumour (FHWT) that has come back (relapsed) will receive a regimen of ICE/Cyclo/Topo, consisting of ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan.
Use the hyperlinks, where available to access additional clinical trial information.
National Cancer Institute (NCI), Children's Oncology Group
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)